Front-line osimertinib improves overall survival in EGFR-mutation positive NSCLC
First-line osimertinib in elderly patients with epidermal growth factor receptor-mutated advanced non-small cell lung cancer: a retrospective multicenter study (HOT2002) | Scientific Reports
Osimertinib in Advanced Lung Cancer with EGFR Mutations - NCI
Clinical efficacy of osimertinib in EGFR-mutant non-small cell lung cancer with distant metastasis | BMC Cancer | Full Text
Effectiveness and safety of osimertinib in patients with metastatic EGFR T790M-positive NSCLC: An observational real-world study | PLOS ONE
Kaplan-Meyer curves for progression free survival of osimertinib by (a)... | Download Scientific Diagram
EGFR-mutant lung cancer: sequencing as a major topic in light of new data - memoinOncology
First-line osimertinib in elderly patients with epidermal growth factor receptor-mutated advanced non-small cell lung cancer: a retrospective multicenter study (HOT2002) | Scientific Reports
EGFR-positive tumors: the issue of optimal therapy across several lines - memoinOncology
Overall survival in enrolled patients treated with osimertinib... | Download Scientific Diagram
Complex EGFR mutations with secondary T790M mutation confer shorter osimertinib progression-free survival and overall survival in advanced non-small cell lung cancer - Lung Cancer
Osimertinib Versus Comparator EGFR TKI as First-Line Treatment for EGFR-Mutated Advanced NSCLC: FLAURA China, A Randomized Study | SpringerLink
Overall survival in patients treated with osimertinib versus... | Download Scientific Diagram
An Early Look at Adjuvant Osimertinib Shows a Dramatic Improvement in Disease-Free Survival - ILCN.org (ILCN/WCLC)
Efficacy of TAGRISSO® (osimertinib) in Metastatic EGFRm NSCLC
Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC | NEJM
Efficacy of Metastatic NSCLC – TAGRISSO® (osimertinib) Nurse Center
ADAURA Establishes Adjuvant Osimertinib as a New Standard of Care for Early-Stage EGFR-Mutated NSCLC
New England Journal of Medicine publishes results of Phase III FLAURA trial in the 1st-line treatment of EGFR-mutated non-small cell lung cancer
Tagrisso demonstrates superiority over chemotherapy in EGFR T790M mutation-positive non-small cell lung cancer
Efficacy of Resectable NSCLC – TAGRISSO® (osimertinib) Nurse Center
FLAURA trial: overall survival results confirms the efficacy of osimertinib in the treatment of NSCLC - Daily Reporter
Overall survival benefit of osimertinib and clinical value of upfront cranial local therapy in untreated EGFR‐mutant nonsmall cell lung cancer with brain metastasis - Zhao - 2022 - International Journal of Cancer -
Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC | NEJM
